Home/SERB Pharmaceuticals/Dr. Vignesh Rajah

DV

Dr. Vignesh Rajah

Chief Medical Officer

SERB Pharmaceuticals

Therapeutic Areas

Emergency Medicine Oncology Rare Neurologic Diseases Rare Metabolic Disorders

SERB Pharmaceuticals Pipeline

Drug	Indication	Phase
Antidote & CBRN Portfolio	Various poisonings and chemical/biological/radiological/nuclear threats	Approved
DANYELZA® (naxitamab)	Neuroblastoma	Approved
OMBLASTYS® (omburtamab)	CNS/Leptomeningeal metastases from neuroblastoma	Approved

Leadership Team at SERB Pharmaceuticals

Dr. Peter C. Adamson

Non-Executive Director (US Board)

View full SERB Pharmaceuticals profile